MARS2

1. 01

   The central dispute is whether selected surgery can continue outside research—not whether surgery should remain routine

2. 02

   Changing the surgical decision can change drug access, referral, staging and diagnostic behavior

3. 03

   Early-stage epithelioid selection is a proposed exception, not a demonstrated rescue of surgery

4. 04

   Systemic-treatment delivery is debated as both a competing explanation and a consequence of surgery

   Sample finding · free

   A podcast host asked whether differing use of postoperative chemotherapy could weaken the MARS 2 comparison, or whether its importance was limited relative to the operation itself.

   Source: podcast, 2024-05-01 · paraphrased; the full report links the source

5. 05

   Expertise arguments intersect with operative extent, diaphragm loss and recovery—not just center volume

   Sample finding · free

   A podcast moderator asked whether the independent monitoring committee had assessed interim data and whether safety concerns warranted stopping the study earlier.

   Source: podcast, 2023-09-26 · paraphrased; the full report links the source

6. 06

   Survival language and crossing-curve analysis are genuine points of disagreement

7. 07

   Quality time, costs and informed choice matter alongside survival—and patient preference does not compel an operation

8. 08

   Systemic treatment is a favored alternative, but histology, toxicity and conditions for holding treatment remain important

9. 09

   Radiotherapy is raised as a next step, but safety, treatment setting and appropriate observation limit the enthusiasm

10. 10

    Intraoperative adjuncts expose a distinct disagreement about benefit, renal harm and unproven less-radical approaches

11. 11

    Global implementation depends on diagnostic concentration, specialist capacity and the feasibility of generating local evidence

12. 12

    Praise for randomized evidence coexists with concern about bias, recruitment communication and the treatment of dissent

The full report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified claims with exact source passages.

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

2021-11-06 → 2026-09-16

Cited window

2023-02-10 → 2026-09-12

Retrieved

2026-10-08

Title

Mesothelioma and Radical Surgery 2: a Multicentre Randomised Trial Comparing (Extended) Pleurectomy Decortication Versus no (Extended) Pleurectomy Decortication for Patients With Malignant Pleural Mesothelioma (Mars 2).

Registry

NCT02040272

Study IDs

MARS2

Sponsor

Royal Brompton & Harefield NHS Foundation Trust

Collaborators

University of Bristol, National Institute for Health Research, United Kingdom

Design

Not applicable · interventional, randomized, parallel, na

Status

Unknown

Enrollment

328 estimated

Start

2015-05

Primary completion

2020-09 estimated

Primary endpoint

Survival

Interventions

1 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.
• –For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
• –24 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.
• –5 further source limits are recorded in the machine-readable scope of this record.
• –The evidence describes reviewed commentary, not a representative survey of HCP opinion, guideline adoption or surgical utilization.
• –Multiple sources may repeat the same person, event or discussion; source counts must not be interpreted as independent clinician counts.
• –Some statements are reported opinions, patient recollections, institutional accounts or anecdotal experiences rather than direct clinician testimony or controlled evidence.
• –Uncertain speakers remain unnamed; adjacent named contributions do not establish who spoke a continuation.
• –Some accounts use inconsistent procedure names, endpoint descriptions or numerical wording. They are retained as commentary rather than silently corrected into trial facts.
• –Several subgroup and cross-study interpretations lack effect estimates, uncertainty intervals or appropriate nonsurgical comparisons in the cited passages.
• –Treatment-access, professional-context and practice descriptions are source- and time-specific, not current global verification.
• –The recruitment publication did not interview over one-third of approached professionals and lacked consultation recordings from half the study sites.
• –Searches may have missed unnamed trial references or transcription variants, and five identified videos could not be reviewed.
• –One podcast's available transcript leaves some speaker identities uncertain; this limits attribution but does not justify assigning those views to rostered participants.

How reports are built and checked: Methods.

Last checked Oct 8, 2026. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch. No corrections.

release 290b3332d75649e30eaf65b95ff0aa9a2bbf2fa29b20c6a08b2971a3aad890fe

The same record as JSON or Markdown, or through the Erudio MCP server.

curl https://www.erudio.com/reports/mars2-nct02040272.json
curl https://www.erudio.com/reports/mars2-nct02040272.md

# MCP (https://mcp.erudio.com/mcp)
get_report_card({ "slug": "mars2-02040272" })